PEPGPepGen Inc.

Nasdaq pepgen.com


$ 13.97 $ 0.67 (5.02 %)    

Friday, 10-May-2024 15:59:41 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 14.01
$ 13.48
$ 0.00 x 0
$ 0.00 x 0
$ 13.26 - $ 14.06
$ 3.72 - $ 17.51
26,528
na
333.38M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-06-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 06-16-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 insiders-buying-gamestop-and-2-other-stocks

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

 pepgen-reported-march-6-q4-2023-gaap-eps-0810-beats-1010-estimate

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.810) per share which beat the analyst consensus estimate of $(1.010) by 1...

 wedbush-maintains-outperform-on-pepgen-lowers-price-target-to-20

Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $21 to $20.

 pepgen-announces-clearance-of-cta-by-uk-medicines--healthcare-products-regulatory-agency-to-begin-connect2-edo51-a-phase-2-clinical-trial-designed-to-support-potential-accelerated-approval-of-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies wi...

 over-37m-bet-on-this-industrial-stock-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades.

 pepgen-reports-pricing-of-offering-of-753m-shares-of-its-common-stock-at-10635-per-share

The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting unde...

 top-4-health-care-stocks-that-may-crash-this-quarter

As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a...

 wedbush-reiterates-outperform-on-pepgen-maintains-21-price-target

Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $21 price target.

 pepgen-announced-first-patient-dosed-in-connect1-edo51-phase-2-clinical-trial-of-pgn-edo51-for-duchenne-muscular-dystrophy-patients-amenable-to-exon-51-skipping

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies wi...

 pepgen-announces-first-patient-dosed-in-phase-1-freedom-dm1-clinical-trial-of-pgn-edodm1-for-myotonic-dystrophy-type-1

- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from F...

 pepgen-q3-earnings-insights
PepGen: Q3 Earnings Insights
11/08/2023 13:30:06

 pepgen-q3-eps-098-misses-088-estimate-ended-q3-with-cash-and-cash-equivalents-of-1295m-with-cash-runway-expected-into-2025

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.88) by 1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION